WestBridge Capital.
The evergreen crossover: a $7bn pool with 20-year holds, 29.7% of Rapido at $3bn, 7.8% of listed PhysicsWallah it refused to sell, and a ~₹4,500 Cr full exit from Aptus that shows it monetises on its own clock, not the IPO window's.
GW GP Score
WestBridge plays a different game from every fund on this page: evergreen capital, crossover public-private mandate, and four co-founders who have worked together for 25 years (including the 2006-11 stint running Sequoia India). It buys at Series A and holds through listing (no OFS at PhysicsWallah, IndiQube or Meesho), then exits listed positions in size when it chooses (Aptus, ~₹4,500 Cr across 2025). The 2025-26 cheques (Juspay at $1.2bn, Rapido to 29.7%, first climate deal in Varaha) show a franchise still concentrating rather than spraying. No fund cycle, no DPI clock, no succession drama: the risk is concentration itself.
Re-up candidate: the realised-cash evidence is doing more work than the brand story.
Portfolio quality depends on a narrow theme; the right comp is concentration risk, not headline unicorn count.
No named analyst override yet; current view is generated from the scored dossier and should be refreshed when the next primary source lands.
Rapido IPO ambitions: a listing would mark the cohort's largest single position.
Vedantu IPO ($100-150M at $500-600M reported): edtech markdown print.
Concentration is the strategy and the risk: Rapido at 29.7% ties a material slice of the book to bike-taxi unit economics.
Computed from current dossier sources; analyst override pending.
The strongest structural position in the cohort: permanent capital, maximum-conviction sizing, real block-sale realisations, and a partnership that has never cracked. Opacity and concentration are the two disciplined caveats.
Rapido, Juspay, PhysicsWallah, IndiQube, Meesho: concentrated and externally validated
Aptus ~₹4,500 Cr full exit; monetises in size, on its own schedule
AI-native repositioning is copy plus two cheques; consumer/fintech core is proven
$7bn evergreen: no raise risk, permanent dry powder
Four co-founders, 25 years, zero churn: the steadiest partnership in Indian capital
Portfolio quality 25% · Exit realisation 30% · Sector positioning 15% · Capital velocity 15% · Franchise stability 15%: see the full GP Score methodology · compare this firm →
Positive catalysts and/or re-up evidence exceed the visible risks, but the score should move only after the named proof lands.
PhysicsWallah liquidity clears with credible OFS/block-sale evidence.
Vedantu IPO ($100-150M at $500-600M reported): edtech markdown print.
Rapido IPO ambitions: a listing would mark the cohort's largest single position.
You can't buy a fund here, but as a benchmark, WestBridge is what patient capital does to Indian venture returns: no forced OFS, block exits at chosen prices. If your GP sells at every IPO window, ask whether that's discipline or fund-clock coercion.
Concentration is the strategy and the risk: Rapido at 29.7% ties a material slice of the book to bike-taxi unit economics.
Rapido IPO ambitions: a listing would mark the cohort's largest single position.
Coverage initiated: inaugural GW GP Score.
Catalyst exposure · latest source pressure
Recent public evidence mapped to this GP. Read this before reading the position table: it is where the score can move next.
Keep the file warm; current events cut both ways or are not yet material enough to move score.
Attribution1 positive catalyst(s), 0 pressure catalyst(s); top driver: India PE-VC value down 5% YoY in H1 CY2026.
The broad private-capital backdrop is selective rather than euphoric; fundraising and mark support now need firm-specific proof.
Score pressureRaises the bar for weak-DPI managers and stale flagship vehicles; rewards funds with fresh closes or visible exits.
Separate broad PE-VC softness from venture AI strength before changing sector-positioning scores.
The funds
$7bn evergreen (firm); ~$10bn India AUM (2022 press reporting) across 1 tracked vehicles.
| Vehicle | Vintage | Size | Stage | Note |
|---|---|---|---|---|
| Evergreen pool (Crossover Fund + AIF I) | evergreen | $7bn | Series A → public | Up-to-20-year horizon; $1.5bn single raise (~2022) was the largest-ever India-focused commitment |
Closest booksProsus Ventures (2 shared) · SoftBank Vision Fund (2 shared) · Creaegis (1 shared)computed · E
Fund analytics · LP underwriting screen
Computed from the public dossier: vehicle cadence, realised exits, mark drift, concentration and franchise stability. All computed signals are GW estimates.
Vehicle cadence is neither freshly restocked nor visibly stale.
Next liquidityPhysicsWallah · IndiQube · Vedantu
3 visible exit events since Jul 2024.
Vehicle cadence is neither freshly restocked nor visibly stale.
7 up / 6 flat / 0 down tracked signals.
No senior departure flagged in key people.
7 up / 6 flat / 0 down
3 events since Jul 2024
Largest tracked active exposure
Higher spread = less balanced franchise
7.8% held; sold nothing in the Nov 2025 IPO; ~3.5-4x paper (E)
27.95% held through the Jul 2025 listing: 'multibagger' (The Arc)
Profitable Q4 FY25; eyeing $100-150M IPO at $500-600M: below the $1bn peak
At least one cited source is dated 2026.
3 visible events tracked.
13 representative positions tracked.
No departure signal structured.
Fund-level DPI/TVPI is usually not public; proxy remains estimated.
Peer median 2 · +1
Peer median 2 · +1
Peer median 74 · +6
Peer median 62 · -7
Peer median 0 · +0
Diligence agenda · how this view can change
The live research question, the proof required, and the source standard. This prevents a GP score from becoming a stale label.
Fund data evidence remains low-confidence despite a scored dossier.
Current · At least one cited source is dated 2026.
Upgrade the weak fields with dated facts before the next score action: Fund data.
Prioritise filings and firm disclosures; mark estimates as GW E until then.
Vedantu IPO ($100-150M at $500-600M reported): edtech markdown print.
PhysicsWallah: next public-market or secondary print
Evidence quality · source file health
How hard the public record is beneath this view: source mix, freshness, low-confidence fields and the next source action.
No primary source structured.
6 total sources · 0% primary
At least one cited source is dated 2026.
Entrackr: WestBridge + Prosus own 56% of Rapido (May 2026)
Find a filing, official firm disclosure, regulator table or LP document before next score action.
Source tiering follows Gravitywell policy: primary = filing/regulator/company disclosure, secondary = reputable media or research, E = Gravitywell estimate. Evidence score is a GW control metric, not an external rating.
The position book
188 portfolio companies all-time (Tracxn); ~132 incl. 104 India startups at the 2022 raise. 13 tracked below.
| Company | Sector | Entered | Entry stage | Status | 12-mo signal | Latest read |
|---|---|---|---|---|---|---|
| Rapido | Consumer & Commerce | 2019 | Series B (led) | Unicorn | ▲ | 29.7% post May-2026 Prosus round at $3bn: 2.7x markup in 20 months; co-held with Nexus |
| PhysicsWallah | Consumer & Commerce | 2022 | Series A (led, $100M) | Public | ▲ | 7.8% held; sold nothing in the Nov 2025 IPO; ~3.5-4x paper (E) |
| Meesho | Consumer & Commerce | 2023 | Secondary | Public | ▲ | 3.92% at RHP: bought from Venture Highway in 2023; no OFS sale found |
| Juspay | Fintech | 2026 | Series D | Unicorn | ▲ | $50M sole-investor round at $1.2bn: first unicorn of 2026 |
| IndiQube | Logistics & Infra | 2018 | Series A | Public | ▲ | 27.95% held through the Jul 2025 listing: 'multibagger' (The Arc) |
| Star Health | Fintech | 2018 | Buyout consortium | Public | → | ADDED ~$12M in H1 FY26: crossover conviction buy |
| Vedantu | Consumer & Commerce | 2019 | Series C (co-led) | Unicorn | → | Profitable Q4 FY25; eyeing $100-150M IPO at $500-600M: below the $1bn peak |
| MedPlus | Healthcare | 2015 | Pre-IPO | Public | → | Promoter-side holder via Lone Furrow |
| Keka HR | SaaS & Dev Tools | 2022 | Series A ($57M) | Private | → | India's largest SaaS Series A |
| Credgenics | Fintech | 2023 | Series B (co-led) | Private | → | Collections SaaS; reported 2026 round unverified |
| Third Wave Coffee | Consumer & Commerce | 2021 | Growth | Private | ▲ | $80-100M round with Creaegis closing mid-2026 at $400-500M (E) |
| Varaha | EV & Climate | 2026 | Series B (led) | Private | ▲ | $45M: first climate deal; Global South carbon removal |
| Skit.ai | AI | 2021 | Series B (led) | Private | → | Conversational AI |
Representative tracked positions reconstructed from public disclosures: not the full book. 12-mo signal is a GW estimate of mark direction from round/exit prints (E). Ownership stakes are not shown: not reliably public.
Sector exposure · where the book leans
Share of the tracked active book by normalized sector (GW estimate): read against our sector dossiers for crowding.
New cheques · 2025-26
Seven rounds in twelve months: the most concentrated pacing in the cohort, every cheque a conviction size-up: Juspay solo at $1.2bn, Rapido doubled-down to 29.7%, a first climate bet (Varaha) and a first US AI-infra bet (Nexthop). The site copy now reads 'AI-native innovators from Series A to IPO and beyond': the evergreen is repositioning without rotating.
Prosus-led at $3bn; WestBridge+Prosus own 56%
US AI networking infra
First tranche $20M; with RTP Global, Omnivore
$1.2bn valuation: primary + secondary
Realisation · are LPs getting paid?
The Aptus exit is the model in miniature: build a 28%+ position over a decade, hold through listing, then exit completely in blocks at chosen prices: ~₹4,500 Cr of real cash in one year. Everything else it held through the 2025 IPO window, because an evergreen can. The realisation engine is real; it just doesn't run on the industry's clock.
Remaining 16.46% (~₹2,600 Cr) sold Sep 3-4, 2025: completing a full exit of ~₹4,500 Cr across the year.
12.4% sold for ₹1,906 Cr at ₹307.54 average.
Held everything: the ₹380 Cr OFS was founders-only; stake worth ~₹3,400-3,500 Cr vs ~$100M+ invested (E).
Full exit 2025: the largest single realisation in the cohort's 24-month window
$1.1bn (Sep 2024) → $3bn (May 2026), externally led both times
Evergreen: no fund-level DPI/TVPI exists or is disclosed
No OFS in PhysicsWallah, IndiQube or Meesho: conviction or illiquidity, LPs can't force the question
No fund cycle means no comparable DPI: judge it on realised block sales (Aptus ~₹4,500 Cr, Nazara ₹500 Cr in 2021) and externally-validated markups (Rapido). GW read: the strongest balance-sheet franchise in India venture, with performance opacity as the structural price of the evergreen. E.
What they're doing
Evergreen crossover: Series A to listed equity in one pool, 20-year holds, no exit pressure: structurally unique in India.
Concentrate, then concentrate more: 29.7% of Rapido, 27.95% of IndiQube, sole-investor rounds (Juspay).
Rotate listed positions on own clock: out of Aptus, into Star Health, hold PhysicsWallah.
Broaden carefully: first climate (Varaha) and US AI-infra (Nexthop) cheques in 2026.
What can break
Concentration is the strategy and the risk: Rapido at 29.7% ties a material slice of the book to bike-taxi unit economics.
Evergreen opacity: LPs and counterparties cannot benchmark performance: trust is structural, not evidenced.
Public-position beta: crossover holdings (Star Health, PhysicsWallah, Meesho) move the book with Indian midcap sentiment.
Vedantu's IPO at $500-600M vs the $1bn peak would crystallise the edtech markdown.
Rapido IPO ambitions: a listing would mark the cohort's largest single position.
Vedantu IPO ($100-150M at $500-600M reported): edtech markdown print.
Third Wave Coffee round completion ($80-100M at $400-500M, E).
Reported Credgenics 2026 round: unverified; likely a misdated 2023 round.
Point-in-time discipline: these are the open items we could not verify at the current vintage. They get resolved: confirmed, corrected or dropped, at the next monthly refresh, never silently.
The takes · one screen, three readers
You can't buy a fund here, but as a benchmark, WestBridge is what patient capital does to Indian venture returns: no forced OFS, block exits at chosen prices. If your GP sells at every IPO window, ask whether that's discipline or fund-clock coercion.
WestBridge is the buyer AND the competitor: it purchases secondaries (Meesho from Venture Highway), leads rounds solo, and never needs your syndicate. In any deal it wants, its 20-year horizon out-prices your 10-year fund maths.
Its listed-book rotation is a crossover signal worth tracking: out of housing finance (Aptus), deeper into health insurance (Star Health). The Rapido concentration is the single biggest private bet on Indian mobility economics.
Sourcing. Every figure is sourced and dated. We tier provenance: Primary (official, regulatory, exchange or company filings), Secondary (tier-1 industry research and reputable media), and GW estimate (our own reconstruction or opinion, labelled, never presented as external fact). We prefer primary where it exists, reconcile divergent prints to cited ranges, and hold every number point-in-time: dated, and never silently restated; revisions publish as dated changes.
Fact vs opinion. Facts vs opinion: market sizes, official prints, prices, named deals and agency ratings are sourced facts (Primary/Secondary). Scores, grades, purity weights, scenario paths and indicative sparkline points are Gravitywell's analytical opinion (GW estimate): labelled, not presented as external data.
GW GP Scores are research opinions, not investment advice, not a solicitation, and not an assessment under any SEBI regulation. Dossiers are compiled from public sources believed reliable; firms named did not participate and figures marked E are Gravitywell estimates. Point-in-time: dated to the vintage shown and never silently restated.